
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations
Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices.
- Please summarize the toxicities observed with CD3×CD20 BsAbs.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
3
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
4
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
5






































